- $442.74m
- $331.49m
- $425.17m
- 23
- 52
- 21
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.51 | ||
| Price to Tang. Book | 1.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.04 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -17.27% | ||
| Return on Equity | -29.89% | ||
| Operating Margin | -22.43% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 390.25 | 362.05 | 386.9 | 406.37 | 425.17 | 441.04 | 467.93 | 1.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Directors
- D. Keith Grossman CHM (60)
- Roderick MacLeod CFO (54)
- Lori Ciano CHO (58)
- Christopher Christoforou VPR (51)
- Donald Middlebrook VPR (70)
- Kashif Rashid GCN (47)
- David Caraway OTH (64)
- Niamh Pellegrini OTH (54)
- Michael DeMane LED (64)
- Sridhar Kosaraju DRC (43)
- Frank Fischer IND (79)
- Shawn McCormick IND (56)
- Kevin O'Boyle IND (63)
- Karen Prange IND (57)
- Susan Siegel IND (60)
- Brad Vale IND (68)
- Elizabeth Weatherman IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 4th, 2006
- Public Since
- November 6th, 2014
- No. of Shareholders
- 13
- No. of Employees
- 1,215
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 36,681,392
- Address
- 1800 Bridge Parkway, REDWOOD CITY, 94065
- Web
- https://www.nevro.com
- Phone
- +1 6502510005
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for NVRO
Q1 2024 Nevro Corp Earnings Call
Nevro Corp Annual Shareholders Meeting
Nevro Corp Annual Shareholders Meeting
Q2 2024 Nevro Corp Earnings Release
Similar to NVRO
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
What is the Nevro share price?
As of Today at 19:15 UTC, shares in Nevro are trading at $12.07. This share price information is delayed by 15 minutes.
How has the Nevro share price performed this year?
Shares in Nevro last closed at $12.07 and the price had moved by -63.7% over the past 365 days. In terms of relative price strength the Nevro share price has underperformed the S&P500 Index by -69.79% over the past year.
What are the analyst and broker recommendations for Nevro?
The overall consensus recommendation for Nevro is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nevro dividend yield?
Nevro does not currently pay a dividend.
Does Nevro pay a dividend?
Nevro does not currently pay a dividend.
When does Nevro next pay dividends?
Nevro does not currently pay a dividend.
How do I buy Nevro shares?
To buy shares in Nevro you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nevro?
As of the previous close price of $12.07, shares in Nevro had a market capitalisation of $442.74m.
Where are Nevro shares listed?
Here are the trading details for Nevro:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: NVRO
What kind of share is Nevro?
Based on an overall assessment of its quality, value and momentum Nevro is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nevro share price forecast for 2024?
The analyst consensus target price for shares in Nevro is $17.47. That is 44.74% above the last closing price of $12.07.
Analysts covering Nevro currently have a consensus Earnings Per Share (EPS) forecast of -$2.66 for the next financial year.
What is the trend in the Nevro share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nevro. Over the past six months, its share price has underperformed the S&P500 Index by -36.63%.
As of the last closing price of $12.07, shares in Nevro were trading -33.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nevro PE Ratio?
The Nevro PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nevro?
Nevro's management team is headed by:
- D. Keith Grossman - CHM
- Roderick MacLeod - CFO
- Lori Ciano - CHO
- Christopher Christoforou - VPR
- Donald Middlebrook - VPR
- Kashif Rashid - GCN
- David Caraway - OTH
- Niamh Pellegrini - OTH
- Michael DeMane - LED
- Sridhar Kosaraju - DRC
- Frank Fischer - IND
- Shawn McCormick - IND
- Kevin O'Boyle - IND
- Karen Prange - IND
- Susan Siegel - IND
- Brad Vale - IND
- Elizabeth Weatherman - IND